GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GH Research PLC
Shares of GH Research, a biotech company developing psychedelic-based therapies, reflect high speculative interest in this emerging field of medicine. The price trajectory depends on the results of clinical trials and changes in the regulation of psychoactive substances.
Share prices of companies in the market segment - Pharma psycho
GH Research (GHRS) is a clinical-stage biopharmaceutical company focused on developing new therapeutic approaches for the treatment of mental disorders, particularly depression. We classify it in the Pharmaceuticals/Psychiatry sector. The chart below shows the dynamics of this innovative biotech sector.
Broad Market Index - GURU.Markets
GH Research is an Irish biopharmaceutical company developing psychedelic-based therapies for the treatment of mental disorders, particularly depression. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
GHRS - Daily change in the company's share price GH Research PLC
Shares of GH Research, a company developing psychedelic-based therapies, are experiencing extreme volatility. Change_co measures the market's reaction to news about clinical trials and regulatory changes. This metric is an important component of formulas on System.GURU.Markets that evaluate speculative biotech companies.
Daily change in the price of a set of shares in a market segment - Pharma psycho
GH Research PLC is a biotech company working with psychedelics. This chart highlights the sector's extreme volatility. Comparison with GHRS's performance helps assess it as a high-risk asset, dependent on clinical data and regulatory changes.
Daily change in the price of a broad market stock, index - GURU.Markets
GH Research is a biopharmaceutical company operating in the psychedelic medicine sector. This is a highly speculative and volatile sector. The chart below reflects average fluctuations in this niche, serving as an indicator of risks and investor expectations.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GH Research PLC
GH Research is a biotech company developing psychedelic-based drugs. News of clinical trials in this cutting-edge field triggers sharp stock price movements, which, in turn, contribute to the overall "noise" and market dynamics.
Annual dynamics of market capitalization of the market segment - Pharma psycho
GH Research PLC is a clinical-stage biotech company focused on developing psychedelic-based therapies for mental disorders. Its stock price is entirely speculative and based on investor confidence in the future potential of this innovative, yet controversial, approach.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
GH Research, a biotech company researching psychedelics, is one of the most speculative stories on the market. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and legislative changes surrounding one of the most controversial areas of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GH Research PLC
The market capitalization of GH Research, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its innovative depression drug, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
GH Research operates at the forefront of biotechnology, developing psychedelic drugs for the treatment of mental disorders. This segment is highly volatile and depends on clinical trial results and regulatory decisions. A sector performance chart will show whether the news surrounding psychedelics has been generally positive or whether investors have remained cautious.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
GH Research is a biopharmaceutical company researching psychedelics for the treatment of depression. It's a highly speculative company, with its share price dependent on the success of clinical trials and regulatory changes. Its dynamics are completely disconnected from market cycles and reflect only hopes for a medical revolution.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GH Research PLC
GH Research is a biotech company developing psychedelic-based therapies. Its weekly stock price is highly volatile, driven by news about clinical trials and changes in controlled substance regulations.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
GH Research is a biotech company operating in the controversial field of psychedelic therapy. Comparing its weekly performance to the pharmaceutical sector is pointless. The chart shows how news about clinical trials and legalization are causing its shares to move at their own pace, separate from the industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of GH Research, a company focused on psychedelic therapy, live in a world of their own. Their performance is driven by news about clinical trials. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the market.
Market capitalization of the company, segment and market as a whole
GHRS - Market capitalization of the company GH Research PLC
GH Research's market cap is a focused bet on the use of psychedelics in the treatment of mental disorders. This clinical-stage company's stock price reflects investor expectations for its leading candidate for the treatment of depression. Its volatility is a direct market reaction to trial data and the changing regulatory stance on this class of substances.
GHRS - Share of the company's market capitalization GH Research PLC within the market segment - Pharma psycho
GH Research is a clinical-stage biopharmaceutical company developing innovative treatments for mental disorders using psychedelic compounds. Its stake in the sector reflects investors' faith in the potential of this new class of therapy. The chart below provides an indication of expectations for this revolution in psychiatry.
Market capitalization of the market segment - Pharma psycho
GH Research is a biopharmaceutical company developing psychedelic-based therapies for the treatment of mental disorders. The chart below shows the overall market capitalization of the psychopharmaceutical sector. Its dynamics reflect growing interest in new approaches to psychiatry and investor willingness to fund this innovative field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents scientific research in the field of psychedelic medicine. GH Research is developing a 5-MeO-DMT-based therapy for the treatment of depression. Its volatile line is a clear bet on the results of clinical trials and changing regulatory attitudes toward psychedelics. It visualizes hope for a breakthrough in psychiatry.
Book value capitalization of the company, segment and market as a whole
GHRS - Book value capitalization of the company GH Research PLC
GH Research's book value is its financial reserves, earmarked for clinical trials of innovative drugs for the treatment of mental disorders. This is scientific capital focused on a single goal. The chart below shows how this biotech company manages its "research budget" as it develops psychedelic therapy.
GHRS - Share of the company's book capitalization GH Research PLC within the market segment - Pharma psycho
GH Research develops innovative treatments for mental disorders. Currently, its assets are intellectual property and clinical trial data, not manufacturing plants. The chart shows a minimal share of physical assets, typical for a biotech company focused on R&D.
Market segment balance sheet capitalization - Pharma psycho
Developing psychedelic therapies, like GH Research's, is a science-intensive, not capital-intensive, business. Its value lies in patents and clinical trial results. Compared to the pharmaceutical sector's assets, the company's model appears very "lightweight," as it doesn't require owning large R&D facilities.
Book value of all companies included in the broad market index - GURU.Markets
GH Research's book value isn't derived from its factories, but from capital invested in clinical research into innovative treatments for mental disorders using psychedelic compounds. The company's assets are its financial resources for conducting breakthrough, yet risky, research. The chart illustrates its scale in the new wave of pharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GH Research PLC
For GH Research, which develops psychedelic-based therapies, book value represents its research dollars. A market capitalization greater than book value represents investors' pure bet on the success of its clinical trials and the potential for a revolution in mental health treatment.
Market to book capitalization ratio in a market segment - Pharma psycho
GH Research is a biotech company developing treatments for mental disorders. It has no revenue, and its market cap is based on the success of its clinical trials. This chart shows a typical biotech picture: a huge market valuation with a minimal book value.
Market to book capitalization ratio for the market as a whole
GH Research is a clinical-stage biotech company focused on developing psychedelic-based therapies for mental disorders. Its market valuation is based entirely on the expected success of its clinical trials. This metric demonstrates how valuations in such cutting-edge medical fields can be disconnected from book value and broader market trends.
Debts of the company, segment and market as a whole
GHRS - Company debts GH Research PLC
GH Research, a biopharmaceutical company focused on treating mental disorders, is raising capital to fund its innovative clinical research. For a company without stable sales revenue, debt and equity financing are the only way to advance its developments. This chart reflects its investment needs during the R&D stage.
Market segment debts - Pharma psycho
GH Research is a clinical-stage biotech company focused on developing therapeutics for mental disorders using psychedelic compounds. This cutting-edge but risky sector requires significant capital. The chart shows how the company funds its research, balancing various sources of capital to advance clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GH Research PLC
GH Research is a biotech company focused on developing psychedelic drugs for the treatment of mental disorders. Clinical trials in this new and highly regulated field require significant funding. This chart shows the company's reliance on debt, reflecting its financial risks as it pursues a potential breakthrough in psychiatry.
Market segment debt to market segment book capitalization - Pharma psycho
GH Research is a biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders. Clinical trials in this area are complex and expensive. This chart shows how the company finances its research and development, comparing its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
GH Research is a biopharmaceutical company focused on treating mental disorders with psychedelic compounds. This is a cutting-edge but risky field that requires long-term investment. How much does the company rely on debt financing? This chart allows you to evaluate its financial strategy against the backdrop of overall debt burden in innovative sectors.
P/E of the company, segment and market as a whole
P/E - GH Research PLC
GH Research is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of mental disorders using psychedelic compounds. This chart reflects high speculative investor expectations. The valuation is highly volatile and depends on clinical trial results and regulatory developments.
P/E of the market segment - Pharma psycho
GH Research is a clinical-stage biotechnology company specializing in developing new treatments for mental and neurological disorders using psychedelic compounds. This chart shows the average valuation for psychopharmaceuticals, helping to understand how the market views this cutting-edge yet risky area of research.
P/E of the market as a whole
GH Research is a clinical-stage biopharmaceutical company developing psychedelic-based therapies for mental disorders. This is a highly speculative field. Is the company's valuation in a world of its own, dependent on legalization and research data, or is the overall market appetite for risk, visible in this chart, driving capital flows into such bold ideas?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GH Research PLC
GH Research is a clinical-stage biotech company focused on developing psychedelic-based therapies for mental disorders. This valuation reflects investors' confidence in the potential breakthrough and future commercialization of its drugs, which could radically change the landscape of psychiatry.
%20P%2FE%20GH%20Research%20PLC&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GH-Research-PLC&v=1772623968951 "Chart of the company's future (projected) P/E GH Research PLC")
Future (projected) P/E of the market segment - Pharma psycho
GH Research is a clinical-stage biopharmaceutical company developing innovative treatments for mental disorders, particularly depression, using psychedelic compounds. This chart reflects expectations for the entire psychopharmacology segment, allowing investors to compare their confidence in GH Research's breakthrough technologies with those of their competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772623969088 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
GH Research PLC is a biopharmaceutical company developing psychedelic-based therapies for mental disorders. This is one of the most cutting-edge and speculative fields. This chart shows the general risk tolerance level, which determines whether investors are willing to fund such revolutionary, but highly risky, approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772623969196 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GH Research PLC
GH Research is a biotech company focused on developing therapeutics for mental disorders using psychedelic compounds. While in clinical trials, its financial results reflect R&D expenses. The chart shows the capital burn required to achieve a potential breakthrough in psychiatry.
Profit of companies in the market segment - Pharma psycho
GH Research is a biotech company focused on developing psychedelic drugs for the treatment of mental disorders. This chart shows the overall financial health of the pharmaceutical sector. GH Research's success depends on clinical trial results and changes in the regulatory environment. The sector's profitability impacts the availability of capital for such cutting-edge research.
Overall market profit
GH Research is focused on developing therapeutics for the treatment of mental disorders using psychedelic compounds. Progress in this controversial but promising field is highly dependent on the overall investment climate. This chart reflects the market's appetite for risk: during periods of rising profits, investors are more willing to invest in revolutionary but risky biotech projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GH Research PLC
GH Research is a biotech company focused on developing therapeutics for mental disorders using psychedelic compounds. Its future depends entirely on the success of clinical trials. This chart shows analyst expectations regarding development progress and potential commercialization of their innovative approaches.
%20profit%20of%20the%20company%20GH%20Research%20PLC&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GH-Research-PLC&v=1772623969286 "Graph of future (projected) profit of the company GH Research PLC")
Future (predicted) profit of companies in the market segment - Pharma psycho
GH Research is a clinical-stage biotech company focused on developing psychedelic-based therapies for mental disorders. Its prospects are entirely dependent on the success of its research. This chart shows the sentiment in the sector, reflecting the market's confidence in the commercial potential of this innovative treatment approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772623969297 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
GH Research, a biopharmaceutical company developing therapeutics for mental disorders, is dependent on funding. This chart, showing overall profit expectations, reflects the investment climate. When the economic outlook is positive, investors are more willing to invest in innovative but risky biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772623969322 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GH Research PLC
GH Research is a clinical-stage biopharmaceutical company specializing in developing treatments for mental disorders. Since it has no revenue, this chart is crucial. It shows how investors view the potential of its breakthrough research, assigning value to future sales in a huge and underserved market.
P/S market segment - Pharma psycho
GH Research is a biotech company focused on developing innovative treatments for mental disorders using psychedelic compounds. Its valuation is based on the potential for future breakthrough therapies. This chart shows the average valuation in the sector, providing insight into the high expectations investors have for GH Research's unique approach.
P/S of the market as a whole
GH Research is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapies for mental disorders. For a company with no current revenue, this chart is a mirror image. It reflects the vast gap between the valuations of traditional businesses and the premium the market is willing to pay for a potential game-changer in psychiatry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GH Research PLC
GH Research is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapies for mental disorders. The company's valuation is based almost entirely on the future. This chart reflects investor expectations for successful clinical trials and a revolution in depression treatment.
%20P%2FS%20GH%20Research%20PLC&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GH-Research-PLC&v=1772623969629 "The graph of the company's future (projected) P/S GH Research PLC")
Future (projected) P/S of the market segment - Pharma psycho
GH Research is a clinical-stage biotech company focused on developing new treatments for mental disorders using psychedelic compounds. This chart displays average future revenue projections in the innovative pharmaceutical sector. It provides insight into how the market values GH Research's potential compared to other companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772623969684 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
GH Research is developing innovative treatments for mental disorders using psychedelic compounds. Investor expectations, as reflected in this chart, are largely linked to the prospects for new approaches in medicine. GH Research's progress could radically change the psychiatric drug market, opening up entirely new growth opportunities.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772623969720 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GH Research PLC
This chart shows the revenue of GH Research, a clinical-stage biopharmaceutical company developing treatments for mental disorders using psychedelic compounds. At this stage, its revenue may be zero or comprised of partnership fees, reflecting progress in research and development rather than commercial sales.
Sales of companies in the market segment - Pharma psycho
GH Research PLC is a biopharmaceutical company focused on developing innovative treatments for mental disorders using psychedelic compounds. This chart shows the overall revenue trend in the sector. GH Research is at the forefront of this emerging market, and its clinical successes could lead to the creation of an entirely new class of therapeutics.
Overall market sales
GH Research is a biopharmaceutical company focused on treating mental disorders. Its activities are funded by venture capital. The overall economic situation, reflected in this chart, influences the availability of such funding. During periods of growth, investors are more inclined to support long-term scientific research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GH Research PLC
GH Research is a biotech company developing therapeutics for mental disorders. Its future revenue forecast is based on the expected success of clinical trials and the potential market size for its innovative drugs. The chart visualizes analysts' confidence in its scientific developments.
%20sales%20of%20the%20company%20GH%20Research%20PLC&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GH-Research-PLC&v=1772623969832 "Schedule of future (projected) sales of the company GH Research PLC")
Future (projected) sales of companies in the market segment - Pharma psycho
GH Research is a biotech company focused on developing innovative treatments for mental disorders using psychedelic compounds. The company operates in a revolutionary, yet highly risky, field. The data in the graph reflects expectations for the entire psychopharmacology segment, where GH Research could become a pioneer in transforming approaches to therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772623969864 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
GH Research is developing psychedelic therapy for mental disorders. This is a cutting-edge field of biotech, requiring significant funding and investor confidence in a future breakthrough. This chart illustrates the overall investment climate, which determines whether markets are willing to fund such bold and long-term projects, which could change the paradigm in medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772623969933 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GH Research PLC
GH Research is a biotech company at the forefront of psychedelic research for the treatment of mental disorders. While in the clinical stage, it is actively investing in R&D. This chart shows its operating losses—the price the company pays for developing potentially revolutionary therapies and generating future revenue streams.
Market segment marginality - Pharma psycho
GH Research is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental disorders, particularly depression, using psychedelic compounds. Profitability is a long-term goal. This chart reflects clinical research costs. Investors evaluate it in the context of potential breakthroughs in psychiatry.
Market marginality as a whole
GH Research is a biotech company focused on developing therapeutics for mental disorders using psychedelic compounds. This is a cutting-edge and controversial area of medicine. Compared to this chart, which reflects the current profitability of traditional businesses, GH Research represents a bet on radically new markets that may emerge in the future.
Employees in the company, segment and market as a whole
Number of employees in the company GH Research PLC
GH Research is a biopharmaceutical company developing therapeutics for mental disorders. It operates with a small, highly specialized team focused on clinical trial management. This chart reflects the compact structure typical of biotech companies in clinical development.
Share of the company's employees GH Research PLC within the market segment - Pharma psycho
GH Research is a biotech company at the forefront of psychedelic drug research for the treatment of mental disorders. This metric reflects its share of the total number of researchers in this innovative segment. It speaks to the size of the scientific team conducting complex clinical trials and the company's commitment to developing next-generation therapies.
Number of employees in the market segment - Pharma psycho
GH Research PLC is a biopharmaceutical company developing psychedelic-based therapeutics for the treatment of mental disorders. This chart reflects the current workforce in the nascent psychedelic medicine sector. The growing number of scientists and clinicians here signals a paradigm shift in psychiatry and growing recognition of the therapeutic potential of these compounds.
Number of employees in the market as a whole
GH Research is a biotech company focused on developing therapeutics for mental disorders using psychedelic compounds. This is one of the most innovative and discussed areas in modern medicine. This graph illustrates how new pharmaceutical trends can create entire ecosystems that require scientists, doctors, and specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GH Research PLC (GHRS)
GH Research is a biotech company focused on psychedelic-based treatments for mental disorders. This chart is a prime example of early-stage intellectual capital valuation. The company has no revenue but has promising developments. The chart shows how highly the market values the potential value of its unique research and IP per scientist working on it.
%20of%20the%20company%20GH%20Research%20PLC%20(GHRS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GH-Research-PLC-GHRS&v=1772623970258 "Chart of market capitalization per employee (in thousands of dollars) of the company GH Research PLC (GHRS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
GH Research is a biotech company focused on developing therapies for psychiatric and neurological disorders. Its value is based on its research and development potential. This chart shows how highly investors value its intellectual capital and the potential for developing breakthrough drugs based on its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772623970308 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
GH Research is a biopharmaceutical company developing psychedelic-based therapies for mental disorders. The chart reflects the high valuation of the scientific potential in this emerging field of medicine. The company's entire value is based on the hope for future cures. This indicator demonstrates the enormous value the market places on the research of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772623970353 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GH Research PLC (GHRS)
GH Research is a clinical-stage biotech company focused on developing psychedelic drugs for the treatment of mental disorders. This is pure R&D. This chart illustrates the "cost of innovation"—the amount the company spends on each scientist and physician conducting expensive clinical trials in hopes of creating a breakthrough treatment.
%20Chart%20GH%20Research%20PLC%20(GHRS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GH-Research-PLC-GHRS&v=1772623970366 "Company Profit Per Employee (in thousands of dollars) Chart GH Research PLC (GHRS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
GH Research is a clinical-stage biopharmaceutical company focused on developing psychedelics (specifically, 5-MeO-DMT) for the treatment of mental disorders. This company has a negative loss per employee, reflecting the high costs of conducting clinical trials and research in this emerging field.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772623970401 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
GH Research is a clinical-stage biotech company specializing in the development of psychedelics (based on 5-MeO-DMT) for the treatment of mental disorders. The company is not profitable. This chart shows its capital burn rate: the operating loss per research team leading the development of a new drug through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772623970440 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GH Research PLC (GHRS)
GH Research is a biopharmaceutical company focused on treating mental disorders with psychedelics. This chart reflects the progress of monetizing its research. Currently, revenue is likely coming from partnerships, and the growth in revenue per employee signals the pharmaceutical industry's growing confidence in the therapeutic potential of its developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GH-Research-PLC-GHRS&v=1772623970488 "Sales chart per company employee GH Research PLC (GHRS)")
Sales per employee in the market segment - Pharma psycho
GH Research operates in the cutting-edge and niche field of psychedelic medicine. This chart provides an insight into the productivity of their scientific team. It shows how revenue (possibly from licensing agreements) per researcher compares to the average in the emerging but rapidly growing psychopharmaceutical sector.
Sales per employee for the market as a whole
GH Research (GHRS) is a clinical-stage biopharmaceutical company focused on psychedelic-based therapies for mental disorders. The company currently has no commercial products and, therefore, no revenue. This chart illustrates a classic biotech situation: the research staff generates data and intellectual property, not revenue.
Short shares by company, segment and market as a whole
Shares shorted by company GH Research PLC (GHRS)
GH Research PLC is a clinical-stage biotech company focused on depression treatments using psychedelic compounds. This is a highly speculative area. The bearish sentiment reflected in this chart indicates that investors are betting on clinical trial failure or regulatory hurdles for this class of compounds.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GH-Research-PLC-GHRS&v=1772623970568 "Short Shares Chart for the Company GH Research PLC (GHRS)")
Shares shorted by market segment - Pharma psycho
GH Research is a biotech company developing psychedelic-based drugs (DMT) for the treatment of severe depression. This chart shows short bets. "Shorts" here are bets that their clinical trials will fail or that regulators (FDA, DEA) will never approve psychedelics.
Shares shorted by the overall market
GH Research (GHRS) is a biotech company working in the controversial but trendy field of psychedelics. They develop compounds for the treatment of mental disorders, particularly depression. This chart illustrates the skepticism surrounding this industry. "Bears" are betting that psychedelics will never receive widespread regulatory approval or that scientific data will not support their effectiveness.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GH Research PLC (GHRS)
GH Research is a biotech company developing psychedelics for the treatment of depression. The stock is highly speculative. This chart can soar above 70 on positive R&D news. Oversold territory (<30) often reflects setbacks, delays, or general investor risk aversion in this sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GH-Research-PLC-GHRS&v=1772623970605 "RSI 14 indicator chart for the company's stock GH Research PLC (GHRS)")
RSI 14 Market Segment - Pharma psycho
GH Research (GHRS) is a biotech company and a pioneer in psychedelics. They focus on *DMT* (5-MeO-DMT) for the treatment of severe depression. The RSI_14_Seg for "Pharma psycho" (biotech) shows the overall sentiment. The chart helps us understand: is GHRS's volatility just hype or is the entire sector overheated?
RSI 14 for the overall market
GH Research (GHRS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GHRS (GH Research PLC)
GH Research is a clinical-stage biopharmaceutical company focused on developing psychedelic therapy (based on 5-MeO-DMT) for the treatment of severe depression. This chart reflects analyst consensus. Their price targets are speculative and based on clinical trial data and the potential changing regulatory landscape for psychedelics.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GHRS-GH-Research-PLC&v=1772623970680 "A chart showing analyst consensus forecasts for the expected stock price. GHRS (GH Research PLC)")
The difference between the consensus estimate and the actual stock price GHRS (GH Research PLC)
GH Research (GHRS) is an Irish clinical-stage biotech company researching psychedelics (5-MeO-DMT) for the treatment of severe depression. This chart is a barometer of psychedelic hopes. It measures the gap between the price and the consensus target, reflecting the enormous potential analysts see in their unconventional approach to the central nervous system.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GHRS-GH-Research-PLC&v=1772623970711 "A chart showing the difference between the consensus forecast and the actual stock price. GHRS (GH Research PLC)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
GH Research (GHRS) is a biopharmaceutical company betting on psychedelics. It is developing an inhaled form of DMT for the treatment of severe depression. This chart shows analysts' overall expectations for the psychopharma sector. It reflects whether experts believe in the legalization and medical potential of psychedelic drugs.
Analysts' consensus forecast for the overall market share price
GH Research (GHRS) is a biopharmaceutical company working at the forefront of psychiatry. They are developing new treatments based on psychedelic compounds (DMT) for the treatment of depression. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but regulatory-challenging areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GH Research PLC
GH Research is a biotech company working in the revolutionary but speculative field of psychedelic medicine. Their lead candidate is a 5-MeO-DMT-based therapy for severe depression. This chart represents pure R&D. It likely reflects not revenue, but the market's faith in their clinical trials and their ability to crack this complex market.
AKIMA Market Segment Index - Pharma psycho
GH Research (GHRS) is a clinical-stage biotech focused on psychedelics; the company is developing an innovative inhaled formulation of 5-MeO-DMT (a psychedelic) for the treatment of treatment-resistant depression. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this futuristic (DMT) R&D (GHRS) rate differentiate it from the average pharma company?
The AKIM Index for the overall market
GH Research is a biopharmaceutical company developing treatments for mental disorders using psychedelics (5-MeO-DMT). It's at the cutting edge of neuropsychiatry. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends and risk appetite.
